FS118

We also show that PD-L1, not PD-1, binding drives the LAG-3 reduction on TILs. We hypothesize that the LAG-3 bivalency in the fragment crystallizable region of FS118 allows LAG-3 clustering, which optimizes cleavage by ADAM10/ADAM17 and thus shedding.

P1/2, N=80, Terminated, invoX Pharma Limited | Active, not recruiting --> Terminated; Business Decision

P1/2, N=95, Active, not recruiting, invoX Pharma Limited | Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Jun 2024

FS118 was well tolerated with no DLTs observed up to and including 20 mg/kg QW. Further studies are warranted to determine clinical benefit in patients who have become refractory to anti-PD-(L)1 therapy.

Simultaneously, expanded use should be considered for those with refractory disease, especially if PD-L1 positive. Insights Dual PD-L1/LAG-3 blockade may be an effective treatment strategy for refractory metastatic tumors, including anaplastic thyroid cancer.

P1/2, N=80, Recruiting, F-star Delta Limited | Active, not recruiting --> Recruiting | Phase classification: P1 --> P1/2 | N=43 --> 80 | Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2022

Conclusions Weekly treatment with FS118 was well tolerated up to 20 mg/kg and was associated with pharmacodynamic markers of FS118 activity. Encouraging signs of clinical activity were observed in highly pre-treated patients who had acquired resistance to prior PD-(L)1 therapy.

Conclusions Weekly treatment with FS118 was well tolerated up to 20 mg/kg and was associated with pharmacodynamic markers of FS118 activity. Encouraging signs of clinical activity were observed in highly pre-treated patients who had acquired resistance to prior PD-(L)1 therapy.